Decoy Therapeutics Inc (DCOY) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access DCOY Annual Balance Sheets →
Changes in quarterly balance sheet trends offer perspective on how Decoy Therapeutics Inc balances growth, leverage, and shareholder equity.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Assets
Cash & cash equivalent7.82
Cash, Cash Equivalents Other0.00
Cash & Short-term Investments7.00
Prepaid Expense And Other Assets Current0.54
Total Current Assets8.36
Equipment/Property/Plant Net0.04
Tax Assets, Noncurrent0.00
Other Assets, Noncurrent0.03
Total Assets8.42
Liabilities
Accounts Payable, Current AC0.94
Short-term Debt0.00
Other Liabilities, Current0.38
Deferred Revenue DE3.23
Total Current Liabilities4.55
Total Long-term Debt0.00
Other liabilities, Noncurrent0.00
Related Party Deposit Liabilities0.14
Total Liabilities4.55
Stockholders' Equity
Common Stock Value0.00
Additional Paid In Capital Common Stock100.54
Retained Earnings / Accumulated Deficit-96.67
Other Equity0.00
Common Stockholder's Equity3.88
Total Stockholder's Equity3.88
Liabilities & Stockholder's Equity8.42
4 historic quarters locked

Sign in to unlock the full Decoy Therapeutics Inc balance sheet history.

About Decoy Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-346852

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.